The nephrology drugs market involves the production and sales of prescription and over-the-counter drugs used for the treatment of kidney diseases and renal disorders. Some common nephrology drugs include drugs that treat chronic kidney diseases, immunosuppressants, erythropoiesis-stimulating agents, calcium, phosphate, and vitamin D binders. Nephrology drugs play a vital role in slowing down the progression of chronic kidney disease and reducing excess fluid in the body. The growing prevalence of chronic diseases such as diabetes and hypertension that can lead to kidney damage has created high demand for nephrology drugs.

Global nephrology drugs market is estimated to be valued at USD 17.2 Bn in 2024 and is expected to reach USD 26.9 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

Key Takeaways

Key players operating in the nephrology drugs are Amgen Inc., F. Hoffmann-La Roche Ltd, Sanofi, Novartis AG, AstraZeneca, Pfizer Inc., Johnson and Johnson, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, AbbVie Inc., Genzyme Corporation, Merck and Co. Inc., Bayer AG, Eli Lilly and Company, Fresenius Medical Care AG and Co. KGaA, Shire Pharmaceuticals Limited, Keryx Biopharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd.

The growing prevalence of chronic kidney diseases around the world has increased the demand for nephrology drugs. As per data, chronic kidney disease affected around 10-13% of the global population.

Advancements in drug delivery systems and development of novel drugs with improved efficacy have enhanced the Nephrology Drugs Market Growth. Many pharmaceutical companies are involved in R&D to develop biologics and precision medicines for nephrology.

Market Trends

Growing Geriatric Population - The risk of chronic kidney disease increases with age. As the geriatric population is rising globally, it will surge the demand for nephrology medications over the coming years.
Get More Insights On- Nephrology Drugs Market